Accessibility Menu
 
Arrow-Thin-Down
S&P 500
7,126.06
+1.2%
+84.78
Arrow-Thin-Down
DJI
49,447.43
+1.8%
+868.71
Arrow-Thin-Down
NASDAQ
24,468.48
+1.5%
+365.78
Arrow-Thin-Down
Bitcoin
$76,312.00
-1.8%
-$1,425.50
Arrow-Thin-Down
AMZN
$250.36
+0.3%
+$0.66
Arrow-Thin-Down
GOOG
$339.42
+2.0%
+$6.65
Arrow-Thin-Down
META
$689.14
+1.8%
+$12.27
Arrow-Thin-Down
MSFT
$422.80
+0.6%
+$2.54
Arrow-Thin-Down
NVDA
$201.67
+1.7%
+$3.32
Arrow-Thin-Down
TSLA
$400.41
+3.0%
+$11.51
Most Active StocksDaily Stock GainersDaily Stock Losers

Hims & Hers HUGE Acquisition News!

Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.

By Travis Hoium – Feb 19, 2026 at 3:06PM EST

Key Points

  • Eucalyptus will add $450 million in annual revenue growing at a triple digit rate to Hims & Hers.
  • The risk is in using the $1 billion in cash on the balance sheet to buy more growth.
  • Management isn't shying away from the risks currently facing the business.

Hims & Hers (HIMS +6.45%) announced the $1.15 billion acquisition of Australian telehealth company Eucalyptus, which will add $450 million in annualized revenue to the company. This isn't a company shying away from recent legal action, it's scaling internationally as fast as possible. In this video, I go through the upside from this acquisition as well as the downside of using most of the cash on the balance sheet, which was once a backstop for investors.

*Stock prices used were end-of-day prices of Feb. 19, 2026. The video was published on Feb. 19, 2026.

Read Next

About the Author

Travis Hoium
Travis Hoium is a contributing Motley Fool stock market analyst covering solar energy, technology, and growth stocks. Before The Motley Fool, Travis was a mechanical engineer at 3M and founded a virtual reality company. He holds a bachelor’s degree in mechanical engineering and a master’s degree in business administration from the University of Minnesota.
TMFFlushDraw
X@travishoium

Travis Hoium has positions in Hims & Hers Health. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.

Stocks Mentioned

Hims & Hers Health Stock Quote
Hims & Hers Health
NYSE: HIMS
$28.82
(+6.78%)+$1.83
Novo Nordisk Stock Quote
Novo Nordisk
NYSE: NVO
$40.52
(-1.00%)-$0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services